Previous Article | Next Article ![]()
J Virol, February 1998, p. 986-993, Vol. 72, No. 2
Department of Surgery, Duke University
Medical Center, Durham, North Carolina 27710
Received 3 July 1997/Accepted 22 October 1997
A synthetic peptide, DP178, containing amino acids 127 to 162 of
the human immunodeficiency virus type 1 (HIV-1) gp41 Env glycoprotein,
is a potent inhibitor of virus infection and virus mediated
cell-to-cell fusion (C. Wild, T. Greenwell, and T. Matthews, AIDS Res.
Hum. Retroviruses 9:1051-1053, 1993). In an effort to understand the mechanism of action of this peptide, we derived resistant variants of HIV-1IIIB and NL4-3 by serial virus
passage in the presence of increasing doses of the peptide. Sequence
analysis of the resistant isolates suggested that a contiguous
3-amino-acid sequence within the amino-terminal heptad repeat motif of
gp41 was associated with resistance. Site-directed mutagenesis studies confirmed this observation and indicated that changes in two of these
three residues were necessary for development of the resistant phenotype. Direct binding of DP178 to recombinant protein and synthetic
peptide analogs containing the wild-type and mutant heptad repeat
sequences revealed a strong correlation between DP178 binding and the
biological sensitivity of the corresponding virus isolates to DP178.
The results are discussed from the standpoints of the mechanism of
action of DP178 and recent crystallographic information for a core
structure of the gp41 ectodomain.
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides
and
*
Corresponding author. Mailing address: Center for AIDS
Research, P.O. Box 2926, Department of Surgery, Duke University Medical Center, Durham, NC 27710. Phone: (919) 684-4215. Fax: (919) 684-4288. E-mail: matth006{at}mc.duke.edu.
Present address: Department of Dental Ecology and
Microbiology/Immunology, University of North Carolina at Chapel Hill,
Chapel Hill, NC 27599-7456.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|